Rokszin et al. demonstrated a reduced risk of hematological malignancies (hazard ratio: 0.50 [0.28, 0.88]) in patients treated with SGLT2 inhibitors compared to those on DPP-4i 58. The gene discussed is SLC5A2; the disease is hematologic disorder.